Literature DB >> 10619945

Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer.

I Tosoni1, U Wagner, G Sauter, M Egloff, H Knönagel, G Alund, F Bannwart, M J Mihatsch, T C Gasser, R Maurer.   

Abstract

OBJECTIVE: To assess the reliability of the histological diagnosis of bladder cancer by assessing the interobserver variability of staging and grading in pTa/pT1 tumours and evaluating the clinical significance of discrepancies.
MATERIALS AND METHODS: All sections from 301 superficial bladder carcinomas were reviewed by one pathologist. The prognostic relevance of grade and stage from both the initial and review diagnosis were determined in 128 patients for whom there was long-term follow-up information.
RESULTS: There were significant interobserver differences in both the grading and staging of tumours. From a total of 235 tumours that were initially considered pT1, the reviewer classified 35% as pTa, 56% as pT1, 6% as pT1- (at least pT1), and 3% as pT2-4. In 39% of all biopsies there were interobserver differences in tumour grade. The prognostic significance of grade and stage differed between the initial pathology report and the reviewer's diagnosis. The reviewer's staging allowed a better estimate of the risk of subsequent tumour progression than the initial staging. Progression was significantly more common in 49 tumours in which the reviewer agreed with stage pT1 than in 29 tumours that were down-staged from pT1 to pTa (P = 0.0116). However, the initial tumour grade (P = 0.0386) but not the reviewer's grade (P = 0.2645) was significantly linked to progression.
CONCLUSIONS: These results show that grading and staging by different pathologists have varying prognostic implications. If possible, biopsies from bladder tumours should be independently evaluated by two different pathologists before radical therapy is administered.

Entities:  

Mesh:

Year:  2000        PMID: 10619945     DOI: 10.1046/j.1464-410x.2000.00356.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  21 in total

1.  Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems.

Authors:  J W A Oosterhuis; R F M Schapers; M L G Janssen-Heijnen; R P E Pauwels; D W Newling; F ten Kate
Journal:  J Clin Pathol       Date:  2002-12       Impact factor: 3.411

2.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

3.  Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement.

Authors:  Michelle D Reid; Adeboye O Osunkoya; Momin T Siddiqui; Stephen W Looney
Journal:  Int J Clin Exp Pathol       Date:  2012-10-20

4.  Histologic grading of urothelial papillary neoplasms: impact of combined grading (two-numbered grading system) on reproducibility.

Authors:  Burçin Tuna; Kutsal Yörükoglu; Ender Düzcan; Sait Sen; Nalan Nese; Banu Sarsık; Aysegul Akder; Sehnaz Sayhan; Uğur Mungan; Ziya Kirkali
Journal:  Virchows Arch       Date:  2011-04-12       Impact factor: 4.064

5.  Pathology review impacts clinical management of patients with T1-T2 bladder cancer.

Authors:  Samer L Traboulsi; Fadi Brimo; Yutong Yang; Chelsea Maedler; Noémie Prévost; Simon Tanguay; Armen G Aprikian; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2017-06       Impact factor: 1.862

6.  [Tumors of the urinary system. Current and old problems].

Authors:  S Minner; G Sauter
Journal:  Pathologe       Date:  2009-12       Impact factor: 1.011

Review 7.  Reproducibility and reliability of tumor grading in urological neoplasms.

Authors:  Rainer Engers
Journal:  World J Urol       Date:  2007-09-09       Impact factor: 4.226

8.  Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.

Authors:  M G W Bol; J P A Baak; B van Diermen; S Buhr-Wildhagen; E A M Janssen; K H Kjellevold; A J Kruse; O Mestad; P Øgreid
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

Review 9.  Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.

Authors:  Margaret A Knowles
Journal:  World J Urol       Date:  2007-10-03       Impact factor: 4.226

10.  Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract.

Authors:  C Langner; G Hutterer; T Chromecki; P Rehak; R Zigeuner
Journal:  Virchows Arch       Date:  2006-03-09       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.